The role and usefulness of quality information provided by drug sales representatives is widely recognized within the regulation:<\/span><\/p>\n Ultimately, it is believed that uniting public health in a profitable collaboration between Doctors, Pharmacists and Pharmaceutical Representatives for quality scientific information represents one of the strategic elements for the pursuit of appropriateness, effectiveness and compliance in the use of drugs. Quality information, based on evidence, has the ultimate goal of providing patients with a real advantage in terms of health through the choice of the appropriate drug by the treating physician.<\/span><\/strong><\/span><\/p>\n With regard to the performance of the activity, reference is made to "the limits and methods established by current national and regional laws" with emphasis on what is the subject of scientific information, namely:<\/span><\/p>\n \u2013 Medicines<\/span><\/p>\n \u2013 Foods for special medical purposes<\/span><\/p>\n \u2013 Food and nutritional parapharmaceuticals<\/span><\/p>\n \u2013 Galenic raw materials<\/span><\/p>\n \u2013 Medical devices and medical-surgical aids<\/span><\/p>\n \u2013 In vitro diagnostic medical devices<\/span><\/p>\n In the regulation, in addition to the accreditation procedures subject to attention and carried out by the assigned corporate offices, it is required to be equipped and to wear a special identification card, it is underlined that the visit activity of the ISFs "will take place through individual visits or collegial and multidisciplinary meetings through o an appointment with professionals or within the access time slots set by the OU Director, who will be responsible for each UO\/SD to define a congruous <\/b>hours that do not interfere with the institutional activities which the company specialist must carry out for meetings with the ISFs" and which must be facilitated by the OU directors by making the "time slots and reception methods" public<\/span><\/p>\n While awaiting the operational implementation of the regulation, we believe that it could be an excellent example of regulation for other structures as well.<\/span><\/p>\n PISA Discipline of scientific information on drugs RA 35<\/a><\/strong><\/p>\n![\"\"](\"https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2020\/03\/AOU-Pisa.jpg\")
<\/a>The resolution, after comparison with AIISF\/FEDAIISF (also recognized in the text of the provision) replaces a previous provision which would have effectively prevented the activity of scientific representatives in the important Tuscan hospital.<\/span><\/p>\n